PLX51107 is primarily investigated for its potential in cancer therapy, particularly as a BET (Bromodomain and Extra-Terminal) inhibitor. It targets specific proteins involved in regulating gene expression, which can play a critical role in the growth and survival of cancer cells. By inhibiting these proteins, it may help suppress tumor progression and enhance the effectiveness of other cancer treatments. Research is ongoing to evaluate its efficacy in various cancer types, including hematologic malignancies and solid tumors, with a focus on its ability to disrupt oncogenic pathways and improve patient outcomes.